XML 54 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events (Details) - USD ($)
 1 Months Ended 3 Months Ended
Apr. 14, 2021
Apr. 12, 2021
Apr. 30, 2021
Mar. 31, 2021
Mar. 10, 2021
Feb. 09, 2021
Subsequent Events (Details) [Line Items]            
Upfront license fee       $ 50,000    
Milestone payments       $ 1.9    
License term       10 years    
Agreement expire, term       15 years    
Shares issued (in Shares)         500,000,000 4,276
Agreement description       (A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets with respect to its Z-pod™ technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either party own more than 60% of the interest in the Joint Venture.    
Subsequent Event [Member]            
Subsequent Events (Details) [Line Items]            
Upfront license fee     $ 50,000      
Company paid     $ 12,500      
Sublicense income percentage     25.00%      
Shares issued (in Shares)   500        
Restricted shares (in Shares)   625,000        
Converted shares description the Company converted 4,049 Series C Convertible Preferred Stock into 13,495,014 shares of common stock. Currently, there are 227 shares of the Company’s Series C Convertible Preferred Stock which remain outstanding.